Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) have been given a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four research analysts have rated the stock with a strong buy rating.
Brokerages have set a 1 year consensus price objective of $23.67 for the company, according to Zacks. Zacks has also given Mersana Therapeutics an industry rank of 104 out of 265 based on the ratings given to related companies.
A number of equities research analysts have commented on the company. Wedbush reissued an “outperform” rating and issued a $25.00 target price on shares of Mersana Therapeutics in a report on Monday, July 24th. Leerink Swann assumed coverage on Mersana Therapeutics in a report on Monday, July 24th. They issued an “outperform” rating and a $23.00 target price for the company. J P Morgan Chase & Co assumed coverage on Mersana Therapeutics in a report on Monday, July 24th. They issued an “overweight” rating and a $23.00 target price for the company. Finally, Cowen and Company assumed coverage on Mersana Therapeutics in a report on Monday, July 24th. They issued an “outperform” rating for the company.
Mersana Therapeutics (NASDAQ MRSN) traded down 9.09% during trading on Monday, hitting $15.30. 31,413 shares of the stock traded hands. Mersana Therapeutics has a 12 month low of $12.71 and a 12 month high of $21.01. The stock’s market cap is $347.51 million. The firm’s 50-day moving average is $17.70 and its 200-day moving average is $16.21.
Mersana Therapeutics (NASDAQ:MRSN) last released its earnings results on Friday, August 11th. The company reported ($6.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($5.77). The business had revenue of $3.73 million during the quarter, compared to the consensus estimate of $3.33 million. On average, analysts forecast that Mersana Therapeutics will post ($8.30) EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2017/10/26/mersana-therapeutics-inc-mrsn-receives-average-rating-of-strong-buy-from-brokerages.html.
Several hedge funds have recently made changes to their positions in the company. Citadel Advisors LLC purchased a new position in shares of Mersana Therapeutics in the second quarter valued at $179,000. Goldman Sachs Group Inc. purchased a new position in shares of Mersana Therapeutics in the second quarter valued at $699,000. Laurion Capital Management LP purchased a new position in shares of Mersana Therapeutics in the second quarter valued at $699,000. DekaBank Deutsche Girozentrale purchased a new position in shares of Mersana Therapeutics in the second quarter valued at $676,000. Finally, Victory Capital Management Inc. purchased a new position in shares of Mersana Therapeutics in the second quarter valued at $754,000. Institutional investors and hedge funds own 74.64% of the company’s stock.
Mersana Therapeutics Company Profile
Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.
Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mersana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.